Overview

Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC

Status:
Completed
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
This study determine the maximal tolerate dose
Phase:
Phase 1
Details
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Treatments:
Oxaliplatin
Oxycodone